Preclinical Demonstration of a Novel Treatment with High Efficacy and No Detectable Toxicity for Inflammatory Skin Conditions including Psoriasis

Although the management options for psoriasis have progressed with use of systemic agents, there are few efficacious nonsteroidal topical therapies patients limited or lower grade disease. The effects allopurinol (Allo) and glutathione (GSH) were examined in two different vitro models psoriasis. In first model, human immortalized keratinocytes (HaCaT) treated M5 cocktail (IL-17A, IL-22, oncostatin M, IL-1α, TNF-α) four interventional groups (control, Allo, oxypurinol (Oxy), methotrexate (MTX)). number live dead cells was determined after treatment 48 72 hrs. Allo decreased cell proliferation (total cells) without increasing death compared to both its xanthine oxidase inhibiting metabolite Oxy a standard agent clinical use, MTX. second psoriatic skin equivalent (PSE) culture system, vehicle control, GSH (as monotherapies combination), vitamin D (VitD) 2 6 days followed by histological analysis altered gene expression. combined exposure antipsoriasis VitD inhibition proliferative replicative markers. Histologic examination tissue at resulted loss integrity squamous/epithelial continuity whereas preserved exposure. additional reversed increased thickness dermis layer caused alone. Taken together, this data shows that may synergistic effect low toxicity constitute therapeutic advantage over current inflammatory conditions marked such as